In Reply The focus of our recent article was on clinical decision-making surrounding results of APOE allele testing. Although outside the scope of the original article and this response, in our view, the inference of a label of mild cognitive impairment—solely based on a score on an office screening assessment without regard for other data (including but not limited to normal and stable serial clinical evaluations and neuropsychological testing as described in the article)—is also not warranted.

The brief vignette describes pertinent history and examination data and otherwise notes the patient as “generally healthy,” which we intended to succinctly reflect that the cardinal features of depression were queried, and all were absent except for the cognitive concerns. Although we agree that a psychiatric consultation is reasonable if depression is suspected as a cause or contributor to cognitive concerns, this was not viewed as warranted in this patient.

Parichita Choudhury, MD, MSc
Vijay K. Ramanan, MD, PhD
Bradley F. Boeve, MD

Author Affiliations: Department of Neurology, Mayo Clinic, Rochester, Minnesota.

Corresponding Author: Bradley F. Boeve, MD, 200 First St SW, Rochester, MN 55905 (bboeve@mayo.edu)

Conflict of Interest Disclosures: Dr Boeve reported receiving grants from Biogen, Alector, and EIP Pharma and receiving personal fees from Rainwater Charitable Foundation. No other disclosures were reported.


Guidelines for Letters

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jamanetwork.com/journals/jama/pages/instructions-for-authors. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment are required before publication. Letters should be submitted via the JAMA online submission and review system at https://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.